<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109262</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-39332</org_study_id>
    <secondary_id>NCI-2017-00463</secondary_id>
    <secondary_id>VAR0147</secondary_id>
    <nct_id>NCT03109262</nct_id>
  </id_info>
  <brief_title>Yttrium Y 90 Glass Microspheres PET/CT in Imaging Patients With Liver Tumors</brief_title>
  <official_title>High Quality Imaging and Dosimetry of Yttrium-90 (90Y) SIRT Using a Digital PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies how well yttrium Y 90 glass microspheres positron emission&#xD;
      tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors. Images&#xD;
      produced by PET/CT may provide better information about the distribution of particles, such&#xD;
      as yttrium Y 90 glass microspheres, delivered for selective internal radiation therapy (SIRT)&#xD;
      compared to the technetium Tc-99m albumin aggregated single photon emission computed&#xD;
      tomography (SPECT)/CT images.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the image quality of yttrium Y 90 glass microspheres (90Y) PET/CT post SIRT&#xD;
      images as compared to technetium Tc-99m albumin aggregated (99mTc MAA) SPECT/CT.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the superior accuracy in both distribution and dosimetry of 90Y PET/CT post&#xD;
      SIRT imaging compared to 99mTc MAA planar and SPECT/CT imaging.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Immediately after standard of care SIRT, patients receive yttrium Y 90 glass microspheres and&#xD;
      undergo PET/CT over 30 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Image Quality for 90-Y PET/CT Scans</measure>
    <time_frame>1 day</time_frame>
    <description>Image quality for 90Y PET/CT scan images was assessed relative to the expected image quality of Standard of Care (SoC) 99mTc-MAA SPECT/CT scans. Assessments were conducted at 5, 10, 15 and 20 minutes after infusion. Scans were assessed on a 1 to 5 Likert scale by 2 Nuclear Medicine physicians who were blinded to patient information. The Likert scale for image quality was established as follows:&#xD;
= Non-diagnostic&#xD;
= Suboptimal&#xD;
= Acceptable&#xD;
= Good&#xD;
= Excellent, equivalent to a SoC 99mTc-MAA SPECT/CT scan The scan for each individual participant at each timepoint was scored on the Likert scale, as determined by the 2 Nuclear Medicine physicians. The outcome is reported as the overall mean of the physician determinations for each time point, with standard deviation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiopharmaceutical Dosimetry Accuracy for 90-Y PET/CT Scans and 99mTc-MAA SPECT/CT Scans</measure>
    <time_frame>1 day</time_frame>
    <description>Radiopharmaceutical dosimetry was assessed based on the numerical tumor-absorbed dose value in Gray as calculated by SurePlan (MIM Software Inc, Cleveland, Ohio). The outcome is reported as the median tumor-absorbed dose in Gray, with standard deviation, for both the 90Y PET/CT and 99mTc-MAA SPECT/CT scans.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Primary Malignant Liver Neoplasm</condition>
  <arm_group>
    <arm_group_label>Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive both Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography (CT)</intervention_name>
    <description>As part of PET/CT and SPECT/CT scans.</description>
    <arm_group_label>Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computed Tomography</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
    <other_name>X-ray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography (PET)</intervention_name>
    <description>As part of PET/CT scan</description>
    <arm_group_label>Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>90-Yttrium (Y-90) Glass Microspheres</intervention_name>
    <description>Radiolabel for PET/CT scan</description>
    <arm_group_label>Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans</arm_group_label>
    <other_name>TheraSphere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Technetium 99mTc albumin aggregated (99mTc-MAA)</intervention_name>
    <description>Radiolabel for 99mTc-MAA SPECT/CT Scan</description>
    <arm_group_label>Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans</arm_group_label>
    <other_name>99mTc-MAA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single-photon emission computerized tomography (SPECT) scan</intervention_name>
    <description>As part of SPECT/CT scan</description>
    <arm_group_label>Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans</arm_group_label>
    <other_name>SPECT Scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient provides written informed consent&#xD;
&#xD;
          -  Patient is referred for 90Y SIRT radioembolization of liver tumor(s)&#xD;
&#xD;
          -  Patient is capable of complying with study procedures&#xD;
&#xD;
          -  Patient is able to remain still for duration of imaging procedure (approximately 30&#xD;
             minutes total for digital PET/CT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Iagaru</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Duan H, Khalaf MH, Ferri V, Baratto L, Srinivas SM, Sze DY, Iagaru A. High quality imaging and dosimetry for yttrium-90 ((90)Y) liver radioembolization using a SiPM-based PET/CT scanner. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2426-2436. doi: 10.1007/s00259-021-05188-4. Epub 2021 Jan 14.</citation>
    <PMID>33443618</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <results_first_submitted>August 12, 2021</results_first_submitted>
  <results_first_submitted_qc>August 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2021</results_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrei Iagaru</investigator_full_name>
    <investigator_title>PROFESSOR OF RADIOLOGY (NUCLEAR MEDICINE)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03109262/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03109262/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans</title>
          <description>All participants receive both Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans&#xD;
Computed Tomography (CT): As part of PET/CT and SPECT/CT scans.&#xD;
Positron Emission Tomography (PET): As part of PET/CT scan&#xD;
Single-photon emission computerized tomography (SPECT) scan: As part of SPECT/CT scan&#xD;
90-Yttrium (Y-90) Glass Microspheres: Radiolabel for PET/CT scan&#xD;
Technetium 99mTc albumin aggregated (99mTc-MAA): Radiolabel for 99mTc-MAA SPECT/CT Scan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans</title>
          <description>All participants receive both Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans&#xD;
Computed Tomography (CT): As part of PET/CT and SPECT/CT scans.&#xD;
Positron Emission Tomography (PET): As part of PET/CT scan&#xD;
Single-photon emission computerized tomography (SPECT) scan: As part of SPECT/CT scan&#xD;
90-Yttrium (Y-90) Glass Microspheres: Radiolabel for PET/CT scan&#xD;
Technetium 99mTc albumin aggregated (99mTc-MAA): Radiolabel for 99mTc-MAA SPECT/CT Scan</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Image Quality for 90-Y PET/CT Scans</title>
        <description>Image quality for 90Y PET/CT scan images was assessed relative to the expected image quality of Standard of Care (SoC) 99mTc-MAA SPECT/CT scans. Assessments were conducted at 5, 10, 15 and 20 minutes after infusion. Scans were assessed on a 1 to 5 Likert scale by 2 Nuclear Medicine physicians who were blinded to patient information. The Likert scale for image quality was established as follows:&#xD;
= Non-diagnostic&#xD;
= Suboptimal&#xD;
= Acceptable&#xD;
= Good&#xD;
= Excellent, equivalent to a SoC 99mTc-MAA SPECT/CT scan The scan for each individual participant at each timepoint was scored on the Likert scale, as determined by the 2 Nuclear Medicine physicians. The outcome is reported as the overall mean of the physician determinations for each time point, with standard deviation.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans</title>
            <description>All participants receive both Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans&#xD;
Computed Tomography (CT): As part of PET/CT and SPECT/CT scans.&#xD;
Positron Emission Tomography (PET): As part of PET/CT scan&#xD;
Single-photon emission computerized tomography (SPECT) scan: As part of SPECT/CT scan&#xD;
90-Yttrium (Y-90) Glass Microspheres: Radiolabel for PET/CT scan&#xD;
Technetium 99mTc albumin aggregated (99mTc-MAA): Radiolabel for 99mTc-MAA SPECT/CT Scan</description>
          </group>
        </group_list>
        <measure>
          <title>Image Quality for 90-Y PET/CT Scans</title>
          <description>Image quality for 90Y PET/CT scan images was assessed relative to the expected image quality of Standard of Care (SoC) 99mTc-MAA SPECT/CT scans. Assessments were conducted at 5, 10, 15 and 20 minutes after infusion. Scans were assessed on a 1 to 5 Likert scale by 2 Nuclear Medicine physicians who were blinded to patient information. The Likert scale for image quality was established as follows:&#xD;
= Non-diagnostic&#xD;
= Suboptimal&#xD;
= Acceptable&#xD;
= Good&#xD;
= Excellent, equivalent to a SoC 99mTc-MAA SPECT/CT scan The scan for each individual participant at each timepoint was scored on the Likert scale, as determined by the 2 Nuclear Medicine physicians. The outcome is reported as the overall mean of the physician determinations for each time point, with standard deviation.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.89" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiopharmaceutical Dosimetry Accuracy for 90-Y PET/CT Scans and 99mTc-MAA SPECT/CT Scans</title>
        <description>Radiopharmaceutical dosimetry was assessed based on the numerical tumor-absorbed dose value in Gray as calculated by SurePlan (MIM Software Inc, Cleveland, Ohio). The outcome is reported as the median tumor-absorbed dose in Gray, with standard deviation, for both the 90Y PET/CT and 99mTc-MAA SPECT/CT scans.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Yttrium Y-90 PET/CT</title>
            <description>All participants receive Y-90 PET/CT Scan&#xD;
Computed Tomography (CT): As part of PET/CT scan. Positron Emission Tomography (PET): As part of PET/CT scan&#xD;
90-Yttrium (Y-90) Glass Microspheres: Radiolabel for PET/CT scan</description>
          </group>
          <group group_id="O2">
            <title>99mTc-MAA SPECT/CT Scans</title>
            <description>All participants receive 99mTc-MAA SPECT/CT scan&#xD;
Computed Tomography (CT): As part of SPECT/CT scans. Single-photon emission computerized tomography (SPECT) scan: As part of SPECT/CT scan&#xD;
Technetium 99mTc albumin aggregated (99mTc-MAA): Radiolabel for 99mTc-MAA SPECT/CT Scan</description>
          </group>
        </group_list>
        <measure>
          <title>Radiopharmaceutical Dosimetry Accuracy for 90-Y PET/CT Scans and 99mTc-MAA SPECT/CT Scans</title>
          <description>Radiopharmaceutical dosimetry was assessed based on the numerical tumor-absorbed dose value in Gray as calculated by SurePlan (MIM Software Inc, Cleveland, Ohio). The outcome is reported as the median tumor-absorbed dose in Gray, with standard deviation, for both the 90Y PET/CT and 99mTc-MAA SPECT/CT scans.</description>
          <units>Gray</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.9" spread="99.7"/>
                    <measurement group_id="O2" value="118.9" spread="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans</title>
          <description>All participants receive both Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans&#xD;
Computed Tomography (CT): As part of PET/CT and SPECT/CT scans.&#xD;
Positron Emission Tomography (PET): As part of PET/CT scan&#xD;
Single-photon emission computerized tomography (SPECT) scan: As part of SPECT/CT scan&#xD;
90-Yttrium (Y-90) Glass Microspheres: Radiolabel for PET/CT scan&#xD;
Technetium 99mTc albumin aggregated (99mTc-MAA): Radiolabel for 99mTc-MAA SPECT/CT Scan</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrei Iagaru, PROFESSOR OF RADIOLOGY (NUCLEAR MEDICINE)</name_or_title>
      <organization>Stanford University</organization>
      <phone>1650-725=4711</phone>
      <email>aiagaru@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

